Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis

D Bassler, M Briel, VM Montori, M Lane, P Glasziou… - Jama, 2010 - jamanetwork.com
Context Theory and simulation suggest that randomized controlled trials (RCTs) stopped
early for benefit (truncated RCTs) systematically overestimate treatment effects for the …

[HTML][HTML] Surfactant alteration and replacement in acute respiratory distress syndrome

A Günther, C Ruppert, R Schmidt, P Markart… - Respiratory …, 2001 - Springer
The acute respiratory distress syndrome (ARDS) is a frequent, life-threatening disease in
which a marked increase in alveolar surface tension has been repeatedly observed. It is …

[HTML][HTML] Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia

U Mirastschijski, R Dembinski, K Maedler - Frontiers in medicine, 2020 - frontiersin.org
Corona virus SARS-CoV-2 has already spread around the whole world and is currently, with
no vaccine available yet, unstoppable. As per today, COVID-19 affects more than 3,000,000 …

Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added …

A Ghati, P Dam, D Tasdemir, A Kati, H Sellami… - Current opinion in …, 2021 - Elsevier
Type I and type II pneumocytes are two forms of epithelial cells found lining the alveoli in the
lungs. Type II pneumocytes exclusively secrete 'pulmonary surfactants,'a lipoprotein …

[HTML][HTML] The role of pulmonary surfactants in the treatment of acute respiratory distress syndrome in COVID-19

S Wang, Z Li, X Wang, S Zhang, P Gao… - Frontiers in …, 2021 - frontiersin.org
Lung alveolar type-II (AT-II) cells produce pulmonary surfactant (PS), consisting of proteins
and lipids. The lipids in PS are primarily responsible for reducing the air-fluid surface tension …

Surfactant-replacement therapy for respiratory distress in the preterm and term neonate

WA Engle, Committee on Fetus and Newborn - Pediatrics, 2008 - publications.aap.org
Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and
mortality in preterm infants. Surfactant therapy substantially reduces mortality and respiratory …

A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm …

R Ramanathan, MR Rasmussen… - American journal of …, 2004 - thieme-connect.com
We compared the onset of clinical response and safety of two surfactants, poractant alfa
(Curosurf, Chiesi Pharmaceuticals, Parma, Italy) and beractant (Survanta, Ross …

The physics and physiology of lung surfactants

JA Zasadzinski, J Ding, HE Warriner, F Bringezu… - Current Opinion in …, 2001 - Elsevier
Langmuir monolayers have provided experimentally accessible models for studies of lung
surfactants at the air-alveolus interface since the medical necessity of lung surfactant was …

Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome

S Ardell, RH Pfister, R Soll - Cochrane Database of Systematic …, 2015 - cochranelibrary.com
Background A wide variety of surfactant preparations have been developed and tested
including synthetic surfactants and surfactants derived from animal sources. Although …

Issues in data monitoring and interim analysis of trials.

AM Grant, DG Altman, AB Babiker… - Health technology …, 2005 - researchonline.lshtm.ac.uk
OBJECTIVES: To address issues about data monitoring committees (DMCs) for randomised
controlled trials (RCTs). DATA SOURCES: Electronic databases. Handsearching of selected …